Effective gene-virotherapy for complete eradication of tumor mediated by the combination of hTRAIL (TNFSF10) and plasminogen k5

Molecular Therapy

Volumn 11, Issue 4, 2005, Pages 531-541

  Liu, Xin Yuan ^a,b   Qiu, Song Bo ^a,c   Zou, Wei Gou ^a   Pei, Zi Fei ^a   Gu, Jin Fa ^a   Luo, Chun Xia ^a   Ruan, Hong Mei ^c   Chen, Yu ^a   Qi, Yi Peng ^c   Qian, Cheng ^a,b,d  

^a INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^b ZHEJIANG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c WUHAN UNIVERSITY   (China)

^d UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Angiogenesis; Apoptosis; Cancer gene therapy; Gene virotherapy; hTRAIL; k5; Oncolytic adenovirus; ZD55

Indexed keywords

ADENOVIRUS VECTOR; E1B PROTEIN; ONYX 015; PLASMINOGEN; PLASMINOGEN KRINGLE 5; PROTEIN P53; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER THERAPY; CELL DEATH; COLORECTAL CARCINOMA; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SPECIFICITY; DRUG TARGETING; GENE DELETION; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; TUMOR CELL DESTRUCTION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS REPLICATION;

ADENOVIRIDAE; ADENOVIRUS E1B PROTEINS; ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CARCINOMA; COLORECTAL NEOPLASMS; GENE THERAPY; GENETIC VECTORS; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; PEPTIDE FRAGMENTS; PLASMINOGEN; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA; TUMOR SUPPRESSOR PROTEIN P53; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALIA;

EID: 20144366573     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2004.12.003     Document Type: Article

References (51)

1. D.D. Barker A.J. Berk Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection Virology 156 1987 107-121
2. J.R. Bischoff D.H. Kirn C.C. Heise F. Mccormick Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection Science 274 1996 373-376
3. C. Heise A. Sampson-Johannes A. Williams F. McCormick D.D. Von Hoff D.H. Kirn ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents Nat. Med. 3 1997 639-645
4. C.C. Heise A.M. Williams S. Xue M. Propst D.H. Kirn Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy Cancer Res. 59 1999 2623-2628
5. K.R. Rogulski et al. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy Cancer Res. 60 2000 1193-1196
6. P.A. Vasey et al. Phase I trial of intraperitoneal injection of the E1B-55-kD-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer J. Clin. Oncol. 20 2002 1562-1569
7. F.R. Khuri et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer Nat. Med. 6 2000 879-885
8. J. Nemunaitis et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B55-kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A phase II trial Cancer Res. 60 2000 6359-6366
9. D. Krin R.L. Martuza J. Zwiebel Replication-selective virotherapy for cancer: Biological principles, risk management and future directions Nat. Med. 7 2001 781-787
10. N.A. Habib et al. E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors Hum. Gene Ther. 12 2001 219-226
11. T. Reid et al. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: A phase I trial Gene Ther. 8 2001 1618-1626
12. J. Nemunaitis et al. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: Safety, feasibility and biological activity Gene Ther. 8 2001 746-759
13. S.O. Freytag K.R. Rogulski D.L. Paielli J.D. Gilbert J.H. Kim A novel three-pronged approach to kill cancer cells selectively: Concomitant viral, double suicide gene, and radiotherapy Hum. Gene Ther. 9 1998 1323-1333
14. F. Motoi et al. Effective gene therapy for pancreatic cancer by cytokines mediated by restricted replication-competent adenovirus Hum. Gene Ther. 11 2000 223-235
15. O. Wildner J.C. Morris The role of the E1B 55 kDa gene product in oncolytic adenoviral vectors expressing herpes simplex virus-tk: assessment of antitumor efficacy and toxicity Cancer Res. 60 2000 4167-4174
16. B. Geoerger et al. Oncolytic activity of p53-expressing conditionally replicative adenovirus AdDelta24-p53 against human malignant glioma Cancer Res. 64 2004 5753-5759
17. J.A. Bristol et al. In vitro and in vivo activities of an oncolytic adenoviral vector designed to express GM-CSF Mol. Ther. 7 2003 755-764
18. Z.L. Zhang et al. An armed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral efficacy Cell Res. 13 2003 481-489
19. Z.F. Pei et al. An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice Hepatology 39 2004 1371-1381
20. P. Sova et al. A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases Mol. Ther. 9 2004 496-509
21. S.B. Qiu et al. Combination of gene-virotherapy (ZD55-hTRAIL) and chemotherapy (5-FU) enhances antitumor and oncolytic efficacy in malignant colorectal carcinoma cancer J. Interferon Cytokine Res. 24 2004 219-230
22. C.L. Addison J.L. Bramson M.M. Hitt W.J. Muller J. Gauldie F.L. Graham Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors Gene Ther. 5 1998 1400-1409
23. P.C. Emtage et al. Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models Hum. Gene Ther. 10 1999 697-709
24. I. Narvaiza et al. Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-gamma-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy J. Immunol. 164 2000 3112-3122
25. G. Mazzolini et al. I. Pancreatic cancer escape variants that evade immunogene therapy through loss of sensitivity to IFNgamma-induced apoptosis Gene Ther. 10 2003 1067-1078
26. M. Caruso et al. Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma Proc. Natl. Acad. Sci. USA 93 1996 11302-11306
27. M. Drozdzik et al. Combined gene therapy with suicide gene and interleukin-12 is more efficient than therapy with one gene alone in a murine model of hepatocellular carcinoma J. Hepatol. 32 2000 279-286
28. U. Wilczynska A. Kucharska J. Szary S. Szala Combined delivery of an antiangiogenic protein (angiostatin) and an immunomodulatory gene (interleukin-12) in the treatment of murine cancer Acta Biochim. Pol. 48 2001 1077-1084
29. S.R. Wiley et al. Identification and characterization of a new member of the TNF family that induces apoptosis Immunity 3 1995 673-682
30. T.S. Griffith W.A. Chin G.C. Jackson D.H. Lynch M.Z. Kubin Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells J. Immunol. 161 1998 2833-2840
31. R.M. Pitti S.A. Marsters S. Ruppert C.J. Donahue A. Moore A. Ashkenazi Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family J. Biol. Chem. 271 1996 12687-12690
32. H. Walczak et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo Nat. Med. 5 1999 157-163
33. A. Ashkenazi et al. Safety and antitumor activity of recombinant soluble Apo2 ligand J. Clin. Invest. 104 1999 155-162
34. P. Carmeliet R.K. Jain Angiogenesis in cancer and other diseases Nature 407 2000 249-257
35. H.L. Kong R.G. Crystal Gene therapy strategies for tumor antiangiogenesis J. Natl. Cancer. Inst. 90 1998 273-286
36. C.X. Luo W.G. Zou S.B. Qiu X.Y. Liu J.G. Ma Recombinant kringle 5 of human plasminogen for mammary cancer gene therapy mediated by adenovirus Chin. J. Cancer Biother. (Chinese) 10 2003 9-12
37. G. Gao et al. Down-regulation of vascular endothelial growth factor and up-regulation of pigment epithelium-derived factor: A possible mechanism for the anti-angiogenic activity of plasminogen kringle 5 J. Biol. Chem. 277 2002 9492-9497
38. J.L. Hsieh et al. Gene therapy for bladder cancer using E1B-55 kD-deleted adenovirus in combination with adenoviral vector encoding plasminogen kringles 1-5 Br. J. Cancer 88 2003 1492-1499
39. Y. Cao A. Chen S.S. An R.W. Ji D. Davidson M. Llinas Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth J. Biol. Chem. 272 1997 22924-22928
40. R.M. Lorence P.A. Rood K.W. Kelley Newcastle disease virus as an antineoplastic agent: Induction of tumor necrosis factor-α and augmentation of its cytotoxicity J. Natl. Cancer Inst. 80 1988 1305-1312
41. M.C. Coffey J.E. Strong P.A. Forsyth P.W. Lee Reovirus therapy of tumors with activated Ras pathway Science 282 1998 1332-1334
42. J. Fueyo et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo Oncogene 1 2000 2-12
43. C. Heise et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy Nat. Med. 6 2000 1134-1139
44. M. Gromeier S. Lachmann M.R. Rosenfeld P.H. Gutin E. Wimmer Intergeneric poliovirus recombinants for the treatment of malignant glioma Proc. Natl. Acad. Sci. USA 97 2000 6803-6808
45. P.L. Hallenbeck et al. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma Hum. Gene Ther. 10 1999 1721-1733
46. S. Miyatake A. Iyer R.L. Martuza S.D. Rabkin Transcriptional targeting of herpes simplex virus for cell-specific replication J. Virol. 71 1997 5124-5132
47. T.J. Wickham et al. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins J. Virol. 71 1997 8221-8229
48. N. Alemany D.T. Curiel The development of replicative adenoviruses for cancer therapy Clin. Cancer Res. 6 2000 3395-3399
49. S. Kagawa et al. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene Cancer Res. 61 2001 3330-3338
50. J.W. Lee M. Hampl P. Albert H.A. Fine Antitumor activity and prolonged expression from a TRAIL-expression adenoviral vector Neoplasia 4 2002 312-323
51. T. Yamanaka et al. Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines Hepatology 32 2000 482-490